Coherus BioSciences, Inc. – NASDAQ:CHRS
Coherus BioSciences stock price today
$1.07
-0.41
-28.19%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Coherus BioSciences stock price monthly change
-10.24%
month
Coherus BioSciences stock price quarterly change
-10.24%
quarter
Coherus BioSciences stock price yearly change
-44.61%
year
Coherus BioSciences key metrics
Market Cap | 165.90M |
Enterprise value | 1.02B |
P/E | -2.03 |
EV/Sales | 4.85 |
EV/EBITDA | -4.01 |
Price/Sales | 2.88 |
Price/Book | -4.42 |
PEG ratio | -1.54 |
EPS | -0.7 |
Revenue | 301.87M |
EBITDA | -165.56M |
Income | -59.28M |
Revenue Q/Q | 137.58% |
Revenue Y/Y | 64.63% |
Profit margin | -138.24% |
Oper. margin | -121.72% |
Gross margin | 66.79% |
EBIT margin | -121.72% |
EBITDA margin | -54.85% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCoherus BioSciences stock price history
Coherus BioSciences stock forecast
Coherus BioSciences financial statements
Average Price Target
$6
Potential upside: 460.74%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 58.71M | -42.86M | -73.01% |
|---|---|---|---|
| Sep 2023 | 74.56M | -39.64M | -53.16% |
| Dec 2023 | 91.52M | -79.65M | -87.03% |
| Mar 2024 | 77.06M | 102.87M | 133.49% |
| Jun 2023 | 469591000 | 644.35M | 137.22% |
|---|---|---|---|
| Sep 2023 | 583783000 | 717.38M | 122.89% |
| Dec 2023 | 629604000 | 823.02M | 130.72% |
| Mar 2024 | 763545000 | 845.38M | 110.72% |
| Jun 2023 | -38.91M | 41.36M | 54.32M |
|---|---|---|---|
| Sep 2023 | -54.3M | 50.54M | 11.10M |
| Dec 2023 | -12.93M | 35.20M | 366K |
| Mar 2024 | -46.76M | 202.76M | 887K |
Coherus BioSciences alternative data
| Aug 2023 | 307 |
|---|---|
| Sep 2023 | 294 |
| Oct 2023 | 294 |
| Nov 2023 | 294 |
| Dec 2023 | 299 |
| Jan 2024 | 299 |
| Feb 2024 | 299 |
| Mar 2024 | 306 |
| Apr 2024 | 306 |
| May 2024 | 306 |
| Jun 2024 | 249 |
| Jul 2024 | 249 |
Coherus BioSciences other data
100.00%
0.00%
of CHRS is owned by hedge funds
173
-18
115.14M
-848.92K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 0 | 223100 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | LANFEAR DENNIS M director, officer.. | Common Stock | 258,940 | $1.42 | $366,918 | ||
Sale | LANFEAR DENNIS M director, officer.. | Common Stock | 223,100 | $2.02 | $449,770 | ||
Option | LANFEAR DENNIS M director, officer.. | Common Stock | 41,000 | $1.42 | $58,097 | ||
Option | LANFEAR DENNIS M director, officer.. | Stock Option (Right to Buy) | 299,940 | $1.42 | $425,015 | ||
Option | WAHLSTROM MATS director | Stock Option (Right to Buy) | 29,994 | $2.08 | $62,507 | ||
Sale | STILWELL MCDAVID officer: Chief Financial Officer | Common Stock | 3,507 | $16.8 | $58,918 | ||
Sale | HEALY JAMES director | Common Stock, $0.0001 par value | 286,076 | $16.12 | $4,611,545 | ||
Sale | HEALY JAMES director | Common Stock, $0.0001 par value | 48,329 | $17.17 | $829,809 | ||
Sale | HEALY JAMES director | Common Stock, $0.0001 par value | 100,150 | $18.06 | $1,808,709 | ||
Purchase | STILWELL MCDAVID | Common Stock | 3,700 | $13.42 | $49,669 |
| Patent |
|---|
Grant Filling date: 25 Jun 2020 Issue date: 2 Aug 2022 |
Grant Filling date: 9 Sep 2019 Issue date: 26 Jul 2022 |
Application Filling date: 26 May 2020 Issue date: 30 Jun 2022 |
Application Filling date: 1 May 2020 Issue date: 23 Jun 2022 |
Application Filling date: 27 Dec 2019 Issue date: 23 Jun 2022 |
Application Filling date: 27 Dec 2019 Issue date: 23 Jun 2022 |
Application Filling date: 27 Dec 2019 Issue date: 12 May 2022 |
Grant Filling date: 3 Apr 2018 Issue date: 22 Feb 2022 |
Application Filling date: 17 Jun 2021 Issue date: 10 Feb 2022 |
Grant Filling date: 28 Oct 2016 Issue date: 25 Jan 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 13 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Dennis M. Lanfear (1955) Chairman, Pres & Chief Executive Officer | $1,820,000 |
| Mr. Vladimir Vexler (1958) Chief Scientific Officer | $768,470 |
Top 4 Immunology Stocks Poised For Growth In 2025
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
Pfizer: Seriously Undervalued At Peak Pessimism
FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward
Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
Week In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestments
Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval
Coherus: The Surface Acquisition Is A Distraction
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7B
-
What's the price of Coherus BioSciences stock today?
One share of Coherus BioSciences stock can currently be purchased for approximately $1.07.
-
When is Coherus BioSciences's next earnings date?
Unfortunately, Coherus BioSciences's (CHRS) next earnings date is currently unknown.
-
Does Coherus BioSciences pay dividends?
No, Coherus BioSciences does not pay dividends.
-
How much money does Coherus BioSciences make?
Coherus BioSciences has a market capitalization of 165.90M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.89% to 257.24M US dollars.
-
What is Coherus BioSciences's stock symbol?
Coherus BioSciences, Inc. is traded on the NASDAQ under the ticker symbol "CHRS".
-
What is Coherus BioSciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Coherus BioSciences?
Shares of Coherus BioSciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Coherus BioSciences's key executives?
Coherus BioSciences's management team includes the following people:
- Mr. Dennis M. Lanfear Chairman, Pres & Chief Executive Officer(age: 70, pay: $1,820,000)
- Mr. Vladimir Vexler Chief Scientific Officer(age: 67, pay: $768,470)
-
How many employees does Coherus BioSciences have?
As Jul 2024, Coherus BioSciences employs 249 workers, which is 19% less then previous quarter.
-
When Coherus BioSciences went public?
Coherus BioSciences, Inc. is publicly traded company for more then 10 years since IPO on 6 Nov 2014.
-
What is Coherus BioSciences's official website?
The official website for Coherus BioSciences is coherus.com.
-
Where are Coherus BioSciences's headquarters?
Coherus BioSciences is headquartered at 333 Twin Dolphin Drive, Redwood City, CA.
-
How can i contact Coherus BioSciences?
Coherus BioSciences's mailing address is 333 Twin Dolphin Drive, Redwood City, CA and company can be reached via phone at +65 06493530.
-
What is Coherus BioSciences stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Coherus BioSciences in the last 12 months, the avarage price target is $6. The average price target represents a 460.74% change from the last price of $1.07.
Coherus BioSciences company profile:
Coherus BioSciences, Inc.
coherus.comExchange:
NASDAQ
Full time employees:
235
Industry:
Biotechnology
Sector:
Healthcare
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
333 Twin Dolphin Drive
Redwood City, CA 94065
Redwood City, CA 94065
CIK: 0001512762
ISIN: US19249H1032
CUSIP: 19249H103
